First Week of February 2026 Options Trading For NovoCure (NVCR)

NovoCure (NVCR) is trading at $13.63 and the piece highlights two option-income setups: selling-to-open the $12 put for a $0.90 bid (cost basis $11.10, ~12% OTM) which has a 69% probability of expiring worthless and would yield 7.50% (45.62% annualized) on cash committed; and a covered-call using the $15 strike with a $0.65 bid ( ~10% premium) that would produce a 14.82% total return if called at Feb 2026 and has a 58% chance to expire worthless, representing a 4.77% yield boost (29.01% annualized). The implied volatilities are high (put IV 95%, call IV 73%) versus a trailing 12‑month volatility of 59%, underscoring elevated option premiums and income potential for volatility-focused strategies.

Analysis

Market structure: Elevated option premia (puts IV 95% vs realized 59%) favor option sellers and cash-rich allocators willing to be long equity on assignment; buyers of short-dated yield (covered calls) also win if shares remain range-bound. Short-term losers are directional long-only traders who need large upside (>$15) — covered-call writers cap upside near 10–15% to Feb 2026. This dynamic signals asymmetric demand for downside protection versus limited appetite to pay for outright upside.

Risk assessment: Tail risks are binary regulatory/reimbursement/clinical shocks (FDA/adoption decisions) that could move NVCR >30% within days; implied odds (put OTM exp. worthless 69%) understate single-event jump risk. Immediate (days) risk is gamma/IV swings around news; short-term (months) is trial/reimbursement cadence through 2025; long-term (years) depends on adoption and durable reimbursement, which could swing multiples by >50%. Hidden dependencies include hospital capital cycles and Medicare/insurer pricing policy.

Trade implications: For capital-efficient yield, cash‑secured Feb2026 $12 put sales or buying equity + selling $15 covered calls both produce attractive annualized YieldBoosts (45.6% and 29.0% respectively) provided risk tolerances for assignment/forgone upside. Consider put verticals ($12/$10) to cap downside while harvesting premium if regulatory tail risk is material. Cross‑sector, trim volatile early‑stage device/biotech longs and rotate a portion into idiosyncratic premium harvesting strategies.

Contrarian angles: Market may be overpricing downside skew — realized vol 59% vs put IV 95% implies >35% of premium is fear; selling well-structured, capped downside trades likely profitable absent binary negative catalysts. However, don’t ignore single-event ruin: a negative reimbursement ruling or failed pivotal data would render premia insufficient; historical parallels include device stocks where one payer decision moved valuation 40–80% in 48 hours. Use spreads, position limits, and event-based stop rules.

Key Decisions for Investors

• Sell NVCR Feb 2026 $12 cash-secured puts up to 2% of equity portfolio (collect $0.90, effective basis $11.10). Close or hedge if NVCR < $10 or implied probability of expiring OTM falls below 50% — target expected return ~7.5% to expiry, ~45% annualized.
• Establish a 1% long NVCR position at ~$13.63 and sell Feb 2026 $15 covered calls (collect $0.65). Target total return 14.8% to expiry; if NVCR > $17, buy back calls and reassess fundamentals; if shares drop below $12, roll down or convert to cash‑secured puts.
• If concerned about binary downside, sell a $12/$10 put vertical Feb 2026 (receive net premium < $0.90 but cap assignment risk). Size to 1–2% and treat as premium harvesting with max loss defined (=$2 strike width − premium).
• Reduce exposure to high‑beta device/biotech names (e.g., IBB constituents with >75% IV) by 1–3% and redeploy into structured premium strategies on NVCR and similar single‑name opportunities where IV > realized vol by >25 percentage points.
• Monitor 90‑day catalyst list (next earnings, any FDA/reimbursement calendar) and set automated rules: close naked short puts or buy protective calls if company announces an adverse regulatory headline or if IV for $12 puts spikes >120%.